(Reuters) -The U.S. Food and Drug Administration has allowed the expanded use of Johnson & Johnson's drug, Tremfya, to treat adults with a type of chronic inflammatory bowel disease, the company said ...
Johnson & Johnson (NYSE:JNJ) has received the U.S. FDA approval to expand the label of its dual-acting monoclonal antibody Tremfya (guselkumab) to include adults with moderately to severely active ...
Inflammatory bowel disease (IBD) impacts 1.6 million people in the U.S. — and a new artificial intelligence-generated drug could help alleviate symptoms. Insilico Medicine, an AI-driven biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback